Neuro-oncology
PRINCIPAL INVESTIGATORS
- Carles Majos Torro
- Marta Simo Parra
- Roser Velasco Fargas
CLINICAL RESEARCHERS
- Alejandro Fernandez Coello
- Andreu Gabarrós Canals
- Anna Maria Lucas Calduch
- Carles Mesia Barroso
- Gerard Plans Ahicart
- Albert Pons Escoda
- Noemi Vidal Sarro
- Sergio Villatoro Gomez
PREDOCTORAL RESEARCHERS
- Montserrat Alemany Marti
- Carla Marco Cazcarra
MANAGEMENT SUPPORT
- Sergio Rodriguez Soriano
- Rosó Sala Corominas
Cancer
Oncobell
Scientific production
20
PAPERS
Average IF: 5,55
11
LED PAPERS
Average IF: 3,69
3 PUBLICATIONS IN FIRST DECILE
11 PUBLICATIONS IN FIRST QUARTILE
15 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Velasco,R;Argyriou,AA;Cornblath,DR;Bruna,P;Alberti,P;Rossi,E;Merkies,I et al, Repurposing chemotherapy-induced peripheral neuropathy grading, Eur J Neurol, 2024;31(12):doi:10.1111/ene.16457
- Pons Escoda,A;Garcia Ruiz,A;Naval Baudin,P;Martinez Zalacain,I;Castell,J;Camins,A;Vidal,N et al, Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles, Eur Radiol, 2024;34(8):5320-5330, doi:10.1007/s00330-024-10611-z
- Majós,C;Pons Escoda,A;Naval,P;Güell,A;Lucas,A;Vidal,N;Cos,M et al, Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors, Eur Radiol, 2024;34(4):2174-2182, doi:10.1007/s00330-023-10138-9
- Velasco,R;Marco,C;Domingo Domenech,E;Stradella,A;Santos,C;Laquente,B;Ferrer,G et al, Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug, Eur J Neurol, 2024;31(9):doi:10.1111/ene.16369
- Simo,M;Rodriguez Fornells,A;Navarro,V;Navarro Martin,A;Nadal,E;Bruna,J, Mitigating radiation-induced cognitive toxicity in brain metastases: More questions than answers, Neuro-Oncol. Adv., 2024;6(1):doi:10.1093/noajnl/vdae137
Research highlights
PROJECTS
1 Granted competitive project
4 Ongoing competitive projects
1 started clinical trials
6 ongoing clinical trials
INNOVATION
1 Patent
PUBLISHED WORKS
2 Clinical guidelines
2 Theses
NETWORKS
TNC
EORTC
GEINO
Selected projects
- PI21/00181. Comprensión y modulación de los mecanismos de respuesta senescente en la neuropatía inducida por platinos. Instituto de Salud Carlos III (ISCIII). Budget: 165.770€. 2022-2026. PI: JORDI BRUNA ESCUER.PI24/01279. Estudio exploratorio traslacional para identificar biomarcadores séricos de dolor neuropático asociados a la neuropatía periférica inducida por paclitaxel. Instituto de Salud Carlos III (ISCIII). Budget: 171.250€. 2025-2027. PI: JORDI BRUNA ESCUER/ ROSER VELASCO FARGAS.
- PI24/01279. Estudio exploratorio traslacional para identificar biomarcadores séricos de dolor neuropático asociados a la neuropatía periférica inducida por paclitaxel. Instituto de Salud Carlos III (ISCIII). Budget: 171.250€. 2025-2027. PI: JORDI BRUNA ESCUER/ ROSER VELASCO FARGAS.
- PI24/01375. Identificación de biomarcadores precoces de toxicidad cognitiva inducida por los tratamientos oncológicos en pacientes con adenocarcinoma de pulmón metastásico. Instituto de Salud Carlos III (ISCIII). Budget: 115.000€. 2025-2027. PI: MARTA SIMO PARRA.
- EF-41 KEYN0TE D58. Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma. NOVOCURE GMBH. Budget: 255.840€. 2025- . PI: JORDI BRUNA ESCUER.
- 2227-BTG. LOMUSTINE WITH OR WITHOUT REIRRADIATION FOR FIRST PROGRESSION OF GLIOBLASTOMA: A RANDOMIZED PHASE III STUDY (LEGATO). EORTC AISBL/IVZW. Budget: 10.000,25€. 2024- . PI: ANNA MARIA LUCAS CALDUCH.